The prevalence of<unk>  in the general population is 3–7%, affecting up to 20% of those over 70; 70%–80% of affected individuals are asymptomatic; only a minority ever require revascularisation or amputation.<unk>  affects one in three diabetics over the age of 50. In the US, it affects 12–20 percent of Americans age 65 and older. Around 10 million Americans have<unk> . Despite its prevalence and cardiovascular risk implications, only 25% of<unk>  patients are undergoing treatment. In people aged 40 years and older in the United States in 2000, rates of<unk>  was 4.3%. Rates were 14.5% people aged 70 years or over. Within age groups, rates were generally higher in women than men. Non-Hispanic blacks had a rates of 7.9% compared to 4.4% in Non-Hispanic whites and 3.0% (1.4%–4.6%) in Mexican Americans. The incidence of symptomatic<unk>  increases with age, from about 0.3% per year for men aged 40–55 years to about 1% per year for men aged over 75 years. The prevalence of<unk>  varies considerably depending on how<unk>  is defined, and the age of the population being studied. Diagnosis is critical, as people with<unk>  have a four- to five-fold higher risk of heart attack or stroke. The Diabetes Control and Complications Trial, and the U.K. Prospective Diabetes Study trials, in people with type 1 and type 2 diabetes, respectively, demonstrated that glycemic control is more strongly associated with microvascular<unk>  than macrovascular<unk> . Pathologic changes occurring in small vessels may be more sensitive to chronically elevated glucose levels than is atherosclerosis occurring in larger<unk> es.
Peripheral artery disease
Lumbar spinal stenosis
Chronic venous insufficiency
Varicose veins
Diabetic foot
Spinal stenosis
Diabetic foot ulcer
Raynaud syndrome